Our Pricing

Mounjaro Loftus: Expert Weight Loss Support in Loftus

Published: 5 October 2026

Residents searching for Mounjaro Loftus now have access to a fully UK-registered online pharmacy service offering tirzepatide weight loss injections from £124.99, with free clinical consultations completed in under three minutes. Cured Pharmacy (GPhC 9012511) provides Loftus patients with the same MHRA-licensed Mounjaro prescribed nationwide, delivered discreetly to your door with transparent upfront pricing and expert pharmacist support led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). All prescriptions are subject to approval by our UK-registered clinical team following a comprehensive online assessment.

How to Access Mounjaro Loftus Through Cured Pharmacy

Accessing Mounjaro Loftus has never been simpler for residents seeking clinically proven weight loss treatment. Cured Pharmacy operates a fully digital prescribing service that eliminates the need for in-person GP appointments whilst maintaining the highest standards of clinical safety. Our three-minute online consultation captures your complete medical history, current medications, and weight loss goals, allowing our UK-registered prescribers to assess your suitability for tirzepatide therapy [1].

Once approved, your Mounjaro Loftus prescription is fulfilled using genuine UK-licensed medication sourced directly from authorised wholesalers. We dispatch all orders in 100% discreet packaging with next-day delivery options available across Loftus and surrounding areas. Our transparent pricing model means you see the exact cost—£124.99 for Mounjaro—before completing your consultation, with no hidden fees or surprise charges at checkout. First-time patients benefit from £20 off using code Weightlossnew, reducing your initial investment to £124.99.

Mounjaro Loftus Dosing and Clinical Efficacy

Mounjaro Loftus prescriptions follow the same evidence-based dosing schedule validated in the landmark SURMOUNT trials, which demonstrated average weight reductions of 15-20.9% over 72 weeks depending on maintenance dose [2]. Treatment begins with a 2.5 mg subcutaneous injection once weekly for four weeks, serving as an initiation dose to improve gastrointestinal tolerability. Your prescriber then escalates the dose in 2.5 mg increments every four weeks, progressing through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and ultimately 15 mg based on your individual response and tolerability.

Tirzepatide's dual mechanism—activating both GIP and GLP-1 receptors—delivers superior weight loss compared to GLP-1 monotherapy in head-to-head trials [3]. Patients typically notice appetite reduction within the first week, with measurable weight loss appearing by week four. Clinical trials showed 91% of participants achieved at least 5% body weight reduction, whilst 63% achieved 20% or greater loss at the maximum dose. These outcomes require adherence to a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme.

Personalising Your Mounjaro Loftus Treatment Plan

Our clinical team tailors every Mounjaro Loftus prescription to your unique metabolic profile and weight loss objectives. Patients with significant cardiovascular risk factors may benefit from slower dose escalation, whilst those experiencing excellent tolerability can progress on the standard four-week schedule. We provide ongoing prescriber support throughout your treatment journey, with optional follow-up consultations to adjust dosing, manage side effects, or address any clinical concerns that arise during therapy.

Mounjaro Loftus Side Effects and Safety Considerations

Understanding potential side effects helps Mounjaro Loftus patients manage their treatment effectively. The most common adverse reactions involve the gastrointestinal system—nausea (reported by 12-29% depending on dose), diarrhoea, constipation, and occasional vomiting typically peak during dose escalation phases and diminish with continued use [4]. These effects reflect tirzepatide's mechanism of slowing gastric emptying and are generally mild to moderate in severity.

More serious but rare considerations include acute pancreatitis (discontinue immediately if severe abdominal pain develops), gallbladder disease, and hypoglycaemia when combined with insulin or sulphonylureas. Mounjaro carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains unclear—patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use tirzepatide. Our prescribers screen for these contraindications during your initial Mounjaro Loftus consultation to ensure treatment safety.

Managing Gastrointestinal Effects with Mounjaro Loftus

Practical strategies significantly reduce nausea and digestive discomfort during Mounjaro Loftus therapy. Eat smaller, more frequent meals rather than large portions, avoid high-fat and spicy foods that delay gastric emptying further, and stay well-hydrated throughout the day. Ginger tea, taking injections in the evening, and remaining upright for two hours after eating all help minimise symptoms. If side effects become intolerable, contact our clinical team—we can delay your next dose escalation or maintain your current dose longer to improve tolerability before advancing.

Mounjaro Loftus Pricing and Prescription Process

Cured Pharmacy offers Mounjaro Loftus at £124.99 per four-week supply, representing competitive UK pricing for this premium weight loss treatment. Our transparent cost structure includes the medication, clinical consultation, prescriber review, and discreet home delivery—no separate consultation fees or hidden charges. New patients receive £20 off their first order with code Weightlossnew, reducing the initial month to £124.99 and making evidence-based weight loss therapy more accessible to Loftus residents.

The prescription process begins with our three-minute online assessment covering your weight history, previous diet attempts, current medications, and relevant medical conditions including cardiovascular disease, kidney function, and diabetes status. Our UK-registered prescribers review your submission within hours, approving suitable candidates and providing personalised dosing instructions. Mounjaro Loftus prescriptions are issued for up to three months initially, with ongoing refills available through simplified follow-up consultations as you progress through dose escalation phases [5].

Who Can Use Mounjaro Loftus for Weight Loss?

Mounjaro Loftus prescriptions are clinically appropriate for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. MHRA licensing permits tirzepatide for chronic weight management in conjunction with reduced-calorie diet and increased physical activity, not as monotherapy. Patients must be 18 years or older—tirzepatide safety and efficacy in paediatric populations have not been established.

Certain medical conditions preclude Mounjaro Loftus use, including personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, previous severe hypersensitivity to tirzepatide, and pregnancy or breastfeeding. Our prescribers carefully evaluate renal function, as dose adjustments are not required for mild to moderate impairment but severe kidney disease warrants caution. Patients with a history of pancreatitis, gastroparesis, or inflammatory bowel disease require individualised risk-benefit assessment before initiating treatment [6].

Mounjaro Loftus for Type 2 Diabetes Patients

Loftus residents with type 2 diabetes benefit from tirzepatide's dual action—significant weight loss combined with improved glycaemic control. Clinical trials demonstrated HbA1c reductions of 1.9-2.4% alongside the substantial weight loss, often allowing reduction or discontinuation of other diabetes medications. However, combining Mounjaro Loftus with insulin or sulphonylureas increases hypoglycaemia risk, necessitating proactive dose adjustments of these agents. Our prescribers coordinate with your existing diabetes care team when appropriate to optimise your complete treatment regimen safely.

Mounjaro Loftus vs Alternative Weight Loss Treatments

Comparing Mounjaro Loftus to other licensed weight loss medications helps patients make informed treatment decisions. Tirzepatide consistently outperforms semaglutide (Wegovy) in head-to-head trials, delivering approximately 5% greater total body weight reduction at comparable timepoints [7]. This enhanced efficacy stems from dual GIP/GLP-1 receptor activation versus GLP-1 monotherapy, though both medications share similar side effect profiles and require weekly subcutaneous injection.

Older weight loss options like orlistat (Xenical) and liraglutide (Saxenda) offer more modest results—orlistat produces 3-5% weight loss through fat malabsorption, whilst Saxenda achieves 5-8% reduction with daily injections. For Loftus patients seeking maximum weight loss efficacy with once-weekly convenience, Mounjaro represents the current gold standard, though individual factors including cost, injection frequency preference, and specific contraindications guide optimal treatment selection. Our clinical team discusses all suitable alternatives during your Mounjaro Loftus consultation to ensure you receive the most appropriate therapy for your circumstances [8].

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 5 October 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 5 October 2026]
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 5 October 2026]
4. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial. JAMA, 327(6), 534-545. [accessed 5 October 2026]
5. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. [accessed 5 October 2026]
6. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 402(10402), 613-626. [accessed 5 October 2026]
7. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. [accessed 5 October 2026]
8. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 5 October 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 5 October 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 5 October 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 5 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.